420 with CNW — GOP Congressman Wants Committee Hearing on FDA’s Failure to Enact CBD Rules
The top-ranking Republican on a crucial House committee has written a letter to the committee chair requesting that a hearing be scheduled so that the U.S. Food and Drug Administration (FDA) can explain why it hasn’t established regulations for CBD products as well as the Delta-8 THC products that are currently abundant on the market.
Representative James Comer from Kentucky wants the Oversight and Reform Committee of the House to analyze why the FDA has failed to exercise its oversight/regulatory function over the different products made from hemp, particularly CBD products. The GOP lawmaker adds that as a result of the inaction by the FDA, contaminated products as well as ads targeting kids abound on the market. Mislabeling is also prevalent, he says.
In addition, he states that there is an urgent need to hear from the federal agency so that the committee can confirm that plans are underway to put in place regulatory mechanisms aimed at solving the problem in a way that protects children from the risks they face from such products.
It should be remembered that lawmakers from both sides of the political divide worked in concert to get hemp legalized back in 2018. The same bipartisan effort has also been exerted to advocate for the passing of rules aimed at regulating the different products that are made from hemp. While the FDA is cognizant of this pressure, it has remained silent and hasn’t made any concrete steps to publish any regulatory framework for the CBD sector.
Comer also mentions that many companies are selling products with delta-8 THC, an intoxicating product made from CBD. The legislator points out that delta-8 THC exists in a legal gray area since the farm bill of 2018 doesn’t refer to delta-8 THC. It only caps delta-9 THC at 0.3% for products that are deemed legal under current federal law. The only action that the FDA has so far taken is to write warning letters to some companies have had made unsubstantiated medical claims while marketing their CBD and delta-8 THC products.
Comer has a track record of being an avid supporter of the hemp sector, and he even carried CBD products to a House sitting back in 2019 as he sang the praises of the strides made by Kentucky in developing its hemp sector. Consequently, he can’t be accused of trying to get political capital out of pushing for this hearing at which the FDA will be tasked with explaining its plans for the CBD sector.
If regulations for the cannabidiol sector are enacted, companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) will be in a better position to compete nationally since all companies will be playing by the same rules.
NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
The top-ranking Republican on a crucial House committee has written a letter to the committee chair requesting that a hearing be scheduled so that the U.S. Food and Drug Administration (FDA) can explain why it hasn’t established regulations for CBD products as well as the Delta-8 THC products that are currently abundant on the market.
Representative James Comer from Kentucky wants the Oversight and Reform Committee of the House to analyze why the FDA has failed to exercise its oversight/regulatory function over the different products made from hemp, particularly CBD products. The GOP lawmaker adds that as a result of the inaction by the FDA, contaminated products as well as ads targeting kids abound on the market. Mislabeling is also prevalent, he says.
In addition, he states that there is an urgent need to hear from the federal agency so that the committee can confirm that plans are underway to put in place regulatory mechanisms aimed at solving the problem in a way that protects children from the risks they face from such products.
It should be remembered that lawmakers from both sides of the political divide worked in concert to get hemp legalized back in 2018. The same bipartisan effort has also been exerted to advocate for the passing of rules aimed at regulating the different products that are made from hemp. While the FDA is cognizant of this pressure, it has remained silent and hasn’t made any concrete steps to publish any regulatory framework for the CBD sector.
Comer also mentions that many companies are selling products with delta-8 THC, an intoxicating product made from CBD. The legislator points out that delta-8 THC exists in a legal gray area since the farm bill of 2018 doesn’t refer to delta-8 THC. It only caps delta-9 THC at 0.3% for products that are deemed legal under current federal law. The only action that the FDA has so far taken is to write warning letters to some companies have had made unsubstantiated medical claims while marketing their CBD and delta-8 THC products.
Comer has a track record of being an avid supporter of the hemp sector, and he even carried CBD products to a House sitting back in 2019 as he sang the praises of the strides made by Kentucky in developing its hemp sector. Consequently, he can’t be accused of trying to get political capital out of pushing for this hearing at which the FDA will be tasked with explaining its plans for the CBD sector.
If regulations for the cannabidiol sector are enacted, companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) will be in a better position to compete nationally since all companies will be playing by the same rules.
NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
